ATE327972T1 - Verfahren zur herstellung von optisch-reinen (r)- und (s)- didesmethylsibutramin - Google Patents
Verfahren zur herstellung von optisch-reinen (r)- und (s)- didesmethylsibutraminInfo
- Publication number
- ATE327972T1 ATE327972T1 AT01901941T AT01901941T ATE327972T1 AT E327972 T1 ATE327972 T1 AT E327972T1 AT 01901941 T AT01901941 T AT 01901941T AT 01901941 T AT01901941 T AT 01901941T AT E327972 T1 ATE327972 T1 AT E327972T1
- Authority
- AT
- Austria
- Prior art keywords
- optically pure
- didesmethilsibutramin
- producing optically
- racemic
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
- C07C251/18—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/44—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reduction and hydrolysis of nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/38—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
- C07C47/457—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/480,889 US6399826B1 (en) | 1999-08-11 | 2000-01-11 | Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE327972T1 true ATE327972T1 (de) | 2006-06-15 |
Family
ID=23909753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01901941T ATE327972T1 (de) | 2000-01-11 | 2001-01-10 | Verfahren zur herstellung von optisch-reinen (r)- und (s)- didesmethylsibutramin |
Country Status (12)
Country | Link |
---|---|
US (2) | US6399826B1 (de) |
EP (2) | EP1246789B1 (de) |
JP (1) | JP2003519675A (de) |
AT (1) | ATE327972T1 (de) |
AU (1) | AU782567B2 (de) |
CA (1) | CA2396950A1 (de) |
CY (1) | CY1106150T1 (de) |
DE (1) | DE60120109T2 (de) |
DK (1) | DK1246789T3 (de) |
ES (1) | ES2260195T3 (de) |
PT (1) | PT1246789E (de) |
WO (1) | WO2001051453A1 (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6476078B2 (en) * | 1999-08-11 | 2002-11-05 | Sepracor, Inc. | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction |
US6974838B2 (en) * | 1998-08-24 | 2005-12-13 | Sepracor Inc. | Methods of treating or preventing pain using sibutramine metabolites |
CA2429047A1 (en) * | 2000-11-15 | 2002-05-23 | Tap Pharmaceutical Products, Inc. | Treatment of anti-depression drug-induced sexual dysfunction with apomorphine |
US20050192271A1 (en) * | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
WO2003091207A2 (en) * | 2002-04-10 | 2003-11-06 | Apsinterm, Llc. | Method of preparing amine stereoisomers |
EP1545484A4 (de) * | 2002-10-05 | 2010-01-13 | Hanmi Pharm Ind Co Ltd | Pharmazeutische zusammensetzung mit kristallinem sibutramin-methansulfonat-hemihydrat |
KR100536750B1 (ko) * | 2002-10-05 | 2005-12-16 | 한미약품 주식회사 | 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물 |
CL2004000826A1 (es) * | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
WO2005041988A1 (en) * | 2003-10-22 | 2005-05-12 | University Of Florida | Method and composition for pain amelioration |
US20050209220A1 (en) * | 2004-03-19 | 2005-09-22 | Jeffrey Conforti | Treatment of peripheral neuropathy |
US20060160905A1 (en) * | 2005-01-18 | 2006-07-20 | Bergeron Raymond J Jr | Compositions and methods for inhibiting pain |
AU2005325292A1 (en) | 2005-01-18 | 2006-07-27 | University Of Florida | Compositions and methods for inhibiting pain |
BRPI0716952A2 (pt) | 2006-09-15 | 2013-10-29 | Reviva Pharmaceuticals Inc | Composto, métodos para tratar e/ou prevenir obesidade ou indicação co-mórbida relacionada à obesidade, e para sintetizar derivado de cicloalquilmetilamina |
CN101555214B (zh) * | 2008-04-08 | 2012-07-11 | 北京嘉事联博医药科技有限公司 | 苯基环丁基酰胺衍生物及其光学异构体、制备方法和用途 |
WO2010065889A2 (en) * | 2008-12-06 | 2010-06-10 | Auspex Pharmaceutical | Cyclobutanemethanamine inhibitors of monomine reuptake |
US9119843B2 (en) * | 2009-12-04 | 2015-09-01 | Caliper Life Sciences, Inc. | Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions |
WO2012003501A2 (en) | 2010-07-02 | 2012-01-05 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives |
RU2642074C2 (ru) | 2011-12-30 | 2018-01-24 | Ревива Фармасьютикалс, Инк. | Композиции, синтез и способы применения производных фенилциклоалкилметиламина |
GB202114564D0 (en) * | 2021-10-12 | 2021-11-24 | Actimed Therapeutics Ltd | Oral formulation |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3155670A (en) | 1962-06-22 | 1964-11-03 | Res Lab Dr C Janssen N V | 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes |
US3155669A (en) | 1962-06-22 | 1964-11-03 | Res Lab Dr C Janssen N V | 2, 4, 8-triaza-spiro (4, 5) dec-2-enes |
US3471515A (en) | 1965-02-01 | 1969-10-07 | Sandoz Ag | (2-hydroxy-3-substituted aminopropoxy)indoles |
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
GB1308191A (en) | 1970-04-06 | 1973-02-21 | Science Union & Cie | Thiochroman derivatives and a process for preparing them |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
DE3008993A1 (de) | 1980-03-08 | 1981-10-01 | Röhm Pharma GmbH, 6100 Darmstadt | Pharmazeutische zubereitungen |
ZA821577B (en) * | 1981-04-06 | 1983-03-30 | Boots Co Plc | Therapeutic agents |
IE52768B1 (en) | 1981-04-06 | 1988-02-17 | Boots Co Ltd | 1-arylcyclobutylalkylamine compounds useful as therapeutic agents |
JPS5940638A (ja) | 1982-08-30 | 1984-03-06 | Fuji Photo Film Co Ltd | 直接ポジ用ハロゲン化銀写真乳剤 |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
GB8501192D0 (en) * | 1985-01-17 | 1985-02-20 | Boots Co Plc | Therapeutic agents |
GB8531071D0 (en) | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
GB8704777D0 (en) | 1987-02-28 | 1987-04-01 | Boots Co Plc | Medical treatment |
JP2675573B2 (ja) | 1988-03-31 | 1997-11-12 | 科研製薬株式会社 | 脳機能改善剤 |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IE61928B1 (en) | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
GB8909209D0 (en) | 1989-04-22 | 1989-06-07 | Wyeth John & Brother Ltd | Piperazine derivatives |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
US5104899A (en) | 1990-08-13 | 1992-04-14 | Sepracor, Inc. | Methods and compositions for treating depression using optically pure fluoxetine |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
EP0554172B1 (de) | 1992-01-28 | 1998-04-29 | Fujitsu Limited | Plasma Farbanzeige-Vorrichtung von Oberflächenentladungs-Typ |
US5780051A (en) | 1992-04-02 | 1998-07-14 | Dynagen, Inc. | Methods and articles of manufacture for nicotine cessation and monitoring nicotine use |
CA2138998A1 (en) | 1992-06-23 | 1994-01-06 | James W. Young | Methods and compositions for treating depression and other disorders using optically pure(-) sibutramine |
AU4542993A (en) | 1992-06-23 | 1994-01-24 | Sepracor, Inc. | Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
US5459164A (en) | 1994-02-03 | 1995-10-17 | Boots Pharmaceuticals, Inc. | Medical treatment |
GB9402641D0 (en) | 1994-02-11 | 1994-04-06 | Boots Co Plc | Therapeutic agents |
CA2134038C (en) | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentiation of drug response |
AU3354895A (en) | 1994-09-19 | 1996-04-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel medicinal use of 5ht3 antagonist |
GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
GB9524681D0 (en) | 1995-12-02 | 1996-01-31 | Knoll Ag | Chemical process |
DE19632423A1 (de) | 1996-08-12 | 1998-02-19 | Merck Patent Gmbh | Thienopyrimidine |
GB9619757D0 (en) | 1996-09-21 | 1996-11-06 | Knoll Ag | Chemical process |
GB9619962D0 (en) | 1996-09-25 | 1996-11-13 | Knoll Ag | Medical treatment |
GB9619961D0 (en) | 1996-09-25 | 1996-11-13 | Knoll Ag | Medical treatment |
US5795880A (en) | 1996-12-30 | 1998-08-18 | Louisiana State University Medical Center Foundation | Method and composition for treating obesity and related disorders in animals comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent |
US6127363A (en) | 1997-10-28 | 2000-10-03 | Vivus, Inc. | Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction |
GB9727131D0 (en) | 1997-12-24 | 1998-02-25 | Knoll Ag | Therapeutic agents |
GB2340037A (en) | 1998-07-30 | 2000-02-16 | Glaxo Group Ltd | Compositions comprising bupropion for the treatment of premature ejaculation |
US6331571B1 (en) * | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
US6046242A (en) * | 1998-11-27 | 2000-04-04 | Basf Aktiengesellschaft | Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence |
WO2000056150A1 (en) | 1999-03-19 | 2000-09-28 | Knoll Pharmaceutical Company | Treatment of premenstrual syndrome |
US6355685B1 (en) | 1999-03-19 | 2002-03-12 | Knoll Pharmaceutical Company | Method of treating anxiety disorders |
AU3899100A (en) | 1999-03-19 | 2000-10-09 | Knoll Pharmaceutical Company | Treatment of hyperactivity disorders |
AU3899200A (en) | 1999-03-19 | 2000-10-09 | Knoll Gmbh | Treatment to lower platelet adhesiveness |
AU3898600A (en) | 1999-03-19 | 2000-10-09 | Knoll Pharmaceutical Company | Method of treating obsessive-compulsive disorder |
ATE294573T1 (de) | 1999-03-19 | 2005-05-15 | Abbott Gmbh & Co Kg | Verwendung von sibutramin oder dessem derivat zur behandlung von schlafstörungen |
AU3760900A (en) | 1999-03-19 | 2000-10-09 | Knoll Pharmaceutical Company | Treatment of menstrual function |
US6346549B1 (en) | 1999-03-19 | 2002-02-12 | Knoll Pharmaceutical Company | Treatment of pharmacology of drug misuse and other addictive disorders |
WO2000056309A1 (en) | 1999-03-19 | 2000-09-28 | Knoll Pharmaceutical Company | Method of treating sexual dysfunction |
EP1178789B1 (de) | 1999-03-19 | 2008-07-16 | Abbott GmbH & Co. KG | Methoden zur behandlung der essstörungen |
CZ20013284A3 (cs) | 1999-03-19 | 2002-10-16 | Knoll Gmbh | Farmaceutická kompozice pro léčbu osteoartritidy nebo dny |
WO2000056315A1 (en) | 1999-03-19 | 2000-09-28 | Knoll Pharmaceutical Company | Treatment of pain |
AU3898000A (en) | 1999-03-19 | 2000-10-09 | Knoll Pharmaceutical Company | Treatment of neuropathic pain or fibromyalgia |
GB9914742D0 (en) * | 1999-06-24 | 1999-08-25 | Knoll Ag | Therapeutic agents |
-
2000
- 2000-01-11 US US09/480,889 patent/US6399826B1/en not_active Expired - Fee Related
-
2001
- 2001-01-10 DK DK01901941T patent/DK1246789T3/da active
- 2001-01-10 JP JP2001551835A patent/JP2003519675A/ja active Pending
- 2001-01-10 WO PCT/US2001/000762 patent/WO2001051453A1/en active IP Right Grant
- 2001-01-10 EP EP01901941A patent/EP1246789B1/de not_active Expired - Lifetime
- 2001-01-10 DE DE60120109T patent/DE60120109T2/de not_active Expired - Fee Related
- 2001-01-10 EP EP05108783A patent/EP1632471A1/de not_active Withdrawn
- 2001-01-10 AU AU27793/01A patent/AU782567B2/en not_active Ceased
- 2001-01-10 CA CA002396950A patent/CA2396950A1/en not_active Abandoned
- 2001-01-10 ES ES01901941T patent/ES2260195T3/es not_active Expired - Lifetime
- 2001-01-10 AT AT01901941T patent/ATE327972T1/de not_active IP Right Cessation
- 2001-01-10 PT PT01901941T patent/PT1246789E/pt unknown
-
2002
- 2002-06-04 US US10/160,033 patent/US6710087B2/en not_active Expired - Fee Related
-
2006
- 2006-08-30 CY CY20061101224T patent/CY1106150T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1246789A1 (de) | 2002-10-09 |
DE60120109T2 (de) | 2006-10-19 |
DE60120109D1 (de) | 2006-07-06 |
CA2396950A1 (en) | 2001-07-19 |
PT1246789E (pt) | 2006-10-31 |
CY1106150T1 (el) | 2011-06-08 |
WO2001051453A1 (en) | 2001-07-19 |
US6710087B2 (en) | 2004-03-23 |
AU782567B2 (en) | 2005-08-11 |
EP1246789B1 (de) | 2006-05-31 |
US6399826B1 (en) | 2002-06-04 |
ES2260195T3 (es) | 2006-11-01 |
US20020183281A1 (en) | 2002-12-05 |
DK1246789T3 (da) | 2006-09-18 |
JP2003519675A (ja) | 2003-06-24 |
AU2779301A (en) | 2001-07-24 |
EP1632471A1 (de) | 2006-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE327972T1 (de) | Verfahren zur herstellung von optisch-reinen (r)- und (s)- didesmethylsibutramin | |
ATE406360T1 (de) | Antagonisten der opioidrezeptoren | |
CO5680444A2 (es) | Agonista a-2 no sedante 1-(2,3-dimetil-fenil)-etil-1,3-dihidro-imidazol-2-tiona | |
DE602005007339D1 (de) | Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol | |
HUP0300301A2 (hu) | Új (amino-propil)-metil-foszfinsavak | |
EA201200954A1 (ru) | Способ получения полугидрата гидрохлорида (r)-8-хлор-1-метил-2,3,4,5-тетрагидро-1н-3-бензазепина, фармацевтическая композиция на его основе и его применение | |
ATE321024T1 (de) | Verfahren zur herstellung von oxazolidinonverbindungen | |
ATE308522T1 (de) | Opioidrezeptorantagonisten | |
BR0209554A (pt) | Métodos para a preparação de um composto, e composto | |
ATE426594T1 (de) | Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase | |
AR108885A2 (es) | Método para la elaboración de escitalopram | |
MX2022005615A (es) | Derivado triciclico de dihidroimidazopirimidona, metodo de preparacion del mismo, composicion farmaceutica y uso del mismo. | |
ATE466008T1 (de) | P-glycoprotein-inhibitor, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die diesen enthält | |
EA200500690A1 (ru) | Новые соединения пиридопиримидинона, способ их получения и фармацевтические композиции, которые их содержат | |
ATE528301T1 (de) | Verfahren zur herstellung von substituierten sulfoxidzusammensetzungen | |
DE60109494D1 (de) | Verfahren zur herstellung von salbutamolisomeren | |
EA200300272A1 (ru) | Новые производные хиназолина, способ их получения и фармацевтические композиции, содержащие их | |
ATE469887T1 (de) | Substituierte heterocyclische verbindungen und deren verwendung zur behandlung multipler medikamentenresistenz | |
DE60238251D1 (de) | Resolutionsverfahren zur herstellung von (r)-(-)-2-hydroxy-2-(2-chlorophenyl)acetischer saeure | |
BRPI0409333A (pt) | processo para a preparação de fenilamida do ácido 5-(4-fluorofenil)-1-[2-((2r,4r)-4-hidróxi-6-oxo-tetrahid ro-piran-2-il)etil]-2-isopropil-4-fenil-1h-pirrol-3-carb oxìlico | |
MXPA02004538A (es) | 3-amino-1-indanol, metodo de sintetizar el mismo y metodo de resolucion optica. | |
NO20030876L (no) | Fremgangsmåte for racemisering av 1-benzyl-4-(4-fluorfenyl)-3- hydroksymetyl-1,2,3,6-tetrahydropyridin for bruk som mellomprodukt i syntese avparoxetin | |
DE60215763D1 (de) | Verfahren zur herstellung von 1-(3-trifluoromethylphenyl)-propan-2-ol enantiomeren | |
ATE360022T1 (de) | Verfahren zur herstellung von norgalanthamin, ihren isomeren, salzen und hydraten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1246789 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |